Pharmos Corporation was founded in 1990 and is headquartered in Iselin, New Jersey. Pharmos Corporation, a biopharmaceutical company, engages in the discovery and development of novel therapeutic drugs to treat a range of diseases of the nervous system in the United States and Israel. It focuses on the diseases of the nervous system, such as the disorders of the brain-gut axis, pain/inflammation, and autoimmune disorders. Pharmos's lead product candidate includes dextofisopam, a non-serotonergic agent, which is in Phase IIb clinical trials for the treatment of irritable bowel syndrome (IBS). Its product pipeline also includes VPI-013 that completed Phase IIa testing for the treatment of female sexual dysfunction and neuropathic pain; CB2-selective cannabinoids for the treatment of inflammatory/autoimmune diseases; and Tianeptine, which is in Phase I clinical trials for the treatment of IBS and functional dyspepsia. In addition, Pharmos Corporation's products under development comprise Cannabinor that has completed two Phase IIa proof of principle trials for treating pain; and NanoEmulsion drug delivery system, which is in Phase IIa clinical trial for the treatment of knee osteoarthritis. Pharmos's therapeutic drugs are also used to treat autoimmune disorders.

Sanofi-Aventis U.S. is just a subsidiary, but it's still one of the largest pharmaceutical companies in the US. As the US operations of European drugmaker Sanofi-Aventis, the company develops, manufactures, and markets pharmaceutical products. Its production facility in Kansas City, Missouri, is one of Sanofi-Aventis' primary manufacturing sites, and it produces pharmaceuticals for sale in the US and around the world. Some of its key products include sleep aid Ambien, cancer drug Taxotere, and blood thinner Plavix. Sanofi-Aventis US markets its parent's products in the US through its 8,000 field sales professionals.

Volu-Sol Reagents Corp company manufactures diagnostic products for use by clinical laboratories; it also plans to provide personal emergency response products and services for consumers. The company's diagnostic business develops and manufactures chemical reagents, stains, and related equipment used by laboratories to detect certain properties in biological samples in fields such as hematology and microbiology. Volu-Sol's yet to be launched Insight Care services employ biosensors, cell phone, and GPS technology to remotely monitor a client's vital signs and provide assistance. Parent RemoteMDx is spinning off Volu-Sol to shareholders. Founded in 1991, ActiveCare (formerly Volu-Sol) has been aided by some of the world’s largest companies, including Matsushita Electric Works (Panasonic), which was not only an investor in the company, but has helped to shape its technologies.

Ranbaxy Laboratories Limited company is India's largest drug manufacturer, as well as a top global generics producer. Anti-infectives amoxycillin and ciprofloxacin, and cardio drug simvastatin are among Ranbaxy's top sellers; all come in several administration forms. The company also addresses gastrointestinal, musculoskeletal, and central nervous system disorders, as well as diabetes, pain, allergies, and HIV/AIDS. Its R&D focus includes new forms of existing drugs and metabolic disease treatments. The company also has a groundbreaking anti-malarial candidate in late-phase trials. Japanese drugmaker Daiichi Sankyo owns a controlling stake in Ranbaxy.

Telik, Inc. company was founded in 1988 and is based in Palo Alto, California. Telik, Inc., a clinical stage drug development company, focuses on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. Telik company's advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the discovery of small molecule drug candidates.

Botanical Laboratories was founded in 1988 and is led by CEO Jim Thornton, a long-time venture capital investor in the consumer health care sector. Botanical Laboratories, Inc. (BLI) is your garden-variety nutritional supplement maker. It manufactures its own branded nutritional supplements and also offers private label manufacturing of nutritional supplements and homeopathic remedies. BLI's consumer products include dietary supplements distributed under its Wellesse brand and sold at retail food and drug stores, such as CVS and Costco. From capsule to carton, its contract manufacturing division offers customers turnkey production and packaging, development, quality control, and testing services nationwide.

Henderson Morley takes aim at those pesky microscopic parasites we know as viruses. The company researches and develops vaccines and treatments for viral infections by preventing them from replicating once they invade their host cells. One of its lead product candidates is a vaccine for genital herpes that could be used as a preventative or a therapeutic measure. Other candidates target human cytomegalovirus and human papillomavirus. Instead of taking its candidates through all phases of development, Henderson Morley instead looks to out-license its candidates. Chairman Andrew Knight owns 34% of the company.

Minrad International, Inc. company, through its Minrad Inc. subsidiary, develops real-time image guidance products used in anesthesiology, orthopedics, neurosurgery, and interventional radiology. The company's technologies, including its SabreSource system, improve accuracy in surgical procedures and reduce radiation exposure. Minrad also makes handheld surgical instruments and generic inhalation anesthetics used in human and veterinary surgeries. In addition, the company is developing other anesthetic drugs that relieve patients' pain during surgery without the loss of consciousness. Minrad belongs to Indian pharma firm Piramal Healthcare.

ChemoCentryx is focused exclusively on the discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemoattractant receptors. Since its founding, ChemoCentryx has established one of the broadest pipelines of chemokine-based therapeutics in the pharmaceutical industry. This has been based on our pioneering insight into the chemokine system, a complex network of chemokine (CHEMO-attractant cytoKINE) molecules (ligands) and receptors that work together to regulate the movement of immune cells in and out of inflamed tissues. Each of our novel small molecule product candidates is designed to target a specific chemokine or chemoattractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

OrthoLogic Corp., doing business as Capstone Therapeutics, focuses on the development and commercialization of therapeutic peptides and other molecules for patients with under-served conditions. The company's product includes Chrysalin, or TP508, a 23-amino acid synthetic peptide, which is under pre-clinical testing for vascular applications, such as acute myocardial infarction and chronic myocardial ischemia. It also offers AZX100, a synthetic 24-amino acid peptide to relax smooth muscle, which modulates blood pressure and the function of blood vessels, airways, sphincters, the gastrointestinal tract, and the genitourinary tract. AZX100 is also evaluated for medical and commercial applications, such as treatment of pulmonary disease, prevention of hypertrophic and keloid scarring, and intimal hyperplasia. The company was formerly known as IatroMed, Inc. and changed its name to OrthoLogic Corp. in July 1991. OrthoLogic Corp. was founded in 1987 and is based in Tempe, Arizona.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.